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a b s t r a c t
Producing purified human proteins with high yield and purity remains a considerable challenge. We
describe the methods utilized in the Structural Genomics Consortium (SGC) in Oxford, resulting in suc-
cessful purification of 48% of human proteins attempted; of those, the structures of 40% were solved
by X-ray crystallography. The main driver has been the parallel processing of multiple (typically 9–20)
truncated constructs of each target; modest diversity in vectors and host systems; and standardized puri-
fication procedures. We provide method details as well as data on the properties of the constructs leading
to crystallized proteins and the impact of methodological variants. These can be used to formulate guide-
lines for initial approaches to expression of new eukaryotic proteins.
 2010 Elsevier Inc.
1. Introduction
The advent of high-throughput protein crystallography has de-
pended on techniques for systematic expression and purification of
proteins at the multi-milligram scale. While purification proce-
dures have traditionally been developed and optimized for each
individual protein, the introduction of high-efficiency expression
systems and purification tags has allowed a considerable degree
of standardization. Comparative summaries of the methods used
in many structural genomics groups (Berrow et al., 2006; Graslund
et al., 2008) have indicated that a simplified core methodology can
be applied to a wide variety of target proteins. The Structural
Genomics Consortium (SGC) was set up to solve structures of hu-
man proteins with potential therapeutic importance and deposit
the structures in public databases without delay (Abbott, 2005; Ed-
wards, 2009; Williamson, 2000). The specific characteristics of this
effort have been: (1) A focus on human proteins. (2) Aiming to
achieve a success rate of 15–20% of structure determination of pro-
teins from a pre-defined target list. (3) A focus on domains with
known or probable biological function. (4) Analysis of multiple
members of domain families. (5) Production of purified human
proteins for use as reagents in biomedical investigations (Edwards
et al., 2009; Fedorov et al., 2007; Uhlen et al., 2008). These goals
defined a target list with characteristics that differ from the bulk
of targets pursued in other structural genomics efforts, and may re-
quire different approaches for protein production. A particular bar-
rier is the difficulty of expressing human proteins in a soluble form
in Escherichia coli. The SGC operates in three sites, at the Universi-
ties of Oxford and Toronto and the Karolinska Institute. Overall the
SGC has deposited more than 1000 structures. The SGC group in
Oxford has deposited 388 of those, representing 282 distinct pro-
tein domains. More than 300 additional protein domains have been
expressed and purified but have not yielded crystal structures yet.
These proteins provide a rich resource for biochemical investiga-
tions, including biophysical characterization, small-molecule
inhibitor screens, and generation of antibodies. The target areas
investigated at the Oxford group include protein kinases, protein
tyrosine phosphatases, small G-proteins, signaling proteins (RGS,
SOCS, 14-3-3, PDZ domains), oxidoreductases and other metabolic
enzymes, lysine demethylases and DNA helicases. This paper de-
scribes the methods used in expression and purification of human
proteins in the Oxford group. We focus mainly on bacterial expres-
sion and on non-membrane protein domains, with a few com-
ments on expression in the baculovirus vector system.
2. Methods
Detailed materials and methods are presented in the Supple-
mentary material. We present here an overview of the methods
used in our lab (Gileadi et al., 2008) and discuss some of the ratio-
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nale and implications of the methods and reagents selected. The
procedures used are summarized in Table 1.
2.1. Source of cDNA
Human cDNA clones were obtained from various sources. Sixty-
eight percent of cDNA clones used in the SGC were derived from
the MGC and IMAGE collections (Lennon et al., 1996; Temple
et al., 2009); 12% and 6% were obtained from commercial sources
and from individual collaborators, respectively; and the remaining
14% were derived from custom synthesis or from RT-PCR of human
mRNA. The MGC/IMAGE collection has been an invaluable re-
source; occasional clones from the collection are missing or mixed
up (c. 3%), but all viable clones are sequence-verified and fully doc-
umented. Synthetic genes have become more affordable, and offer
full flexibility of DNA sequence optimization and specific mutagen-
esis, as well as access to sequences not represented in available
cDNA collections. Although favoured at an early stage, we found
that many of the commercial sources are less reliable than the
aforementioned sources, and often involve restrictions on use
and distribution that are incompatible with our open source policy.
2.2. Expression vectors and hosts
Expression clones were generated by PCR and ligation-indepen-
dent cloning (LIC) into one or more of a set of vectors. The first
choice of vector is pNIC28-Bsa4. It is derived from the pET28a vec-
tor (Merck), with the expression of the cloned gene driven by the
T7-LacO system. Proteins cloned in this vector are fused to an ami-
no-terminal tag of 23 residues (MHHHHHHSSGVDLGTENLYFQ*SM)
including a hexahistidine (His6) and a TEV-protease cleavage site
(marked with ). Additional features include cloning sites for liga-
tion-independent cloning (LIC) separated by a ‘‘stuffer” fragment
that includes the SacB gene. The SacB protein (levansucrase) con-
verts sucrose into a toxic product, allowing selection for recombi-
nant plasmids on agar plates containing 5% sucrose.
Several alternative expression vectors have been used with se-
lected targets (Table 2). pNIC-CTHF appends a C-terminal tag
including a TEV-protease cleavage site followed by His6 and a flag
epitope. Larger fusion tags include E. coli thioredoxin (combined
with hexahistidine and a TEV cleavage site), GST, and a reversible
streptavidin binding tag (derived from vector pBEN-SBP-SET1,
Stratagene). Baculovirus expression vectors were constructed
based on pFastBac (invitrogen), incorporating the same arrange-
ment of LIC2 cloning sites as the bacterial vectors. We have recently
adopted a highly charged, globular domain termed the Z-basic tag
(Hedhammar and Hober, 2007), which may provide substantial
enrichment of the tagged protein on cation-exchange columns. The
Z-basic domain is flanked by a His6 tag and a TEV cleavage site.
An important consideration in vector construction is the ease of
cloning the same gene fragment into multiple contexts. LIC re-
quires short (12–16 bp) extensions at both ends of the insert that
overlap vector sequences flanking the cloning sites. The vectors
used in the SGC can be divided into three LIC classes (Table 2).
All vectors within a class utilize the same extensions, so the same
PCR fragment can be cloned in parallel into any vector within the
class. In practice, cloning a gene into a series of vectors with a vari-
ety of N-terminal or C-terminal tags requires at most two PCR reac-
tions (and two pairs of primers). We found this to be nearly as
convenient as and more economical than the Gateway system,
while minimizing the insertion of extraneous sequences into the
expressed proteins.
Host cells are derived from BL21(DE3) and Rosetta2 (Merck). A
phage-resistant derivative of BL21(DE3) was isolated in our lab and
termed BL21(DE3)-R3; this bacterial strain was then transformed
with plasmid pRARE2 (isolated from Rosetta2 calls), which carries
seven rare-codon tRNA genes. The resulting chloramphenicol-
resistant strain BL21(DE3)-R3-pRARE2 is the standard expression
host.
2.3. Construct design
One premise of the expression pipeline has been that the pro-
tein is the most important factor in determining the success of
purification and crystallization. Specifically, it was assumed that
cropping a protein into a well-ordered domain may improve the
chances of expressing a soluble, stable protein. To implement this
principle, each target protein was cloned both as a full-length se-
quence and as a series of truncated fragments (Graslund et al.,
2008). Determining the fragment boundaries was based on bioin-
formatic prediction of structured domains, primarily on struc-
ture-informed sequence alignments with proteins of known
structure (GenThreader McGuffin and Jones, 2003), prediction of
secondary structures and intrinsically disordered regions (PsiPred,
DisorPred, FoldIndex (Jones, 1999; McGuffin et al., 2000; Prilusky
et al., 2005), and identification of conserved domains (PFAM,
SMART, CD Finn et al., 2008; Schultz et al., 1998; Marchler-Bauer
and Bryant, 2004). We define a ‘‘fragment” as the segment of the
human gene sequence incorporated into an expression clone; a
‘‘construct” is the fragment cloned in a cloning vector, which typ-
ically appends additional tag sequences on either side. The same
fragment may be used in several distinct constructs which may dif-
fer in the tags or in the host organism (bacteria of baculovirus). Fi-
nally, ‘‘domains” are defined as PFAM-annotated structural
domains, although the true structural domain may consist of more
Table 1
Summary of experimental approaches.
Sourcing human cDNA clones 1. IMAGE collection; 2. Commercial collections 3. Custom gene synthesis 4. PCR/cloning from cDNA.
Construct design Designate 2–5 boundaries on either end, based on predictions of domain boundaries, secondary structure prediction, and sequence
alignment. Generate 9–15 constructs for each target or domain.
Vectors and hosts Primarily E. coli (BL21 derivatives expressing rare-codon tRNAs); alternative expression in baculovirus-infected insect cells is
discussed separately.
Vectors (see Table 2 for details).
Cloning Ligation-independent cloning (LIC), using complementary ssDNA ends generated by T4 DNA polymerase.
Evaluating clones Presence and size of inserts verified by PCR, and a subset of constructs are sequenced.
Soluble protein expression tested in 1-ml cultures or 50-ml cultures. Expression is performed in rich medium (TB) at 18–25 C. The
cells are lysed in mild detergent (BugBuster) followed by NiNTA purification.
Protein expression (E. coli) 1–5 L cultures in TB medium, grown to OD 3 at 37 C. Induction with IPTG at lower temperatures (18–25 C) overnight.
Protein purification (E. coli) Cells are extracted by high-pressure or sonication without detergents. Standard purification includes IMAC and gel filtration at high
salt (0.3–0.5 M NaCl). Some proteins are further treated with TEV protease to remove the tag, then passed through IMAC again to
remove impurities, and gel filtration if necessary. When the standard methods are insufficient, additional steps such as ion exchange,
heparin-Sepharose or Blue-Sepharose may be applied.
2 Abbreviations used: LIC, ligation-independent cloning; PCR, polymerase chain
reaction; TCEP, tris(2-carboxyethyl)phosphine; TEV, tobacco etch virus; aa, amino
acid(s).
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than one PFAM domain. Three to five alternative boundaries were
designated at the predicted boundaries and at nearby positions
(2–10 aa apart), and the resulting 9–15 constructs were then
cloned and tested for expression and solubility in one or more
vectors/hosts. The default cloning vector was pNIC28-Bsa4, which
appends an N-terminal hexahistidine tag. Cloning into alternative
vectors can be done either in parallel or after obtaining unsatisfac-
tory expression results from the primary vector. The order was
normally N-terminal His6, then C-terminal His6, followed by thio-
redoxin or other large tags. If bacterial expression failed, the gene
fragments were cloned into baculovirus vectors.
2.4. Cloning and test expression
As in most large-scale structural genomics projects, we have
adopted ligation-independent cloning methods to provide direc-
tional, in-frame cloning without the specific adjustments required
when ligating restriction sites (Graslund et al., 2008; Gileadi et al.,
2008; Aslanidis, 1990; Dieckman et al., 2002; Stols et al., 2002).
Several groups have adopted the Gateway cloning system (InVitro-
gen), which is ideally suited for cloning the same fragment into
multiple vectors. A disadvantage is the obligatory addition of pep-
tide sequences on one or both ends of the protein, and the use of
relatively expensive proprietary reagents for subcloning. We chose
a method (Aslanidis, 1990; Stols et al., 2002) based on annealing of
short complementary single-stranded 50-tails generated by the 30-
exonuclease activity of T4 DNA polymerase. The method depends
on a 12–16 bp extension added to the PCR primers, which should
be composed of three nucleotides only to control the extent of
T4 digestion. A similar method (InFusion, Clontech) has no restric-
tion on base composition of the extensions. Having produced more
that 40,000 constructs using the T4-based LIC we find that cloning
in multiple vectors is easy and efficient, and that the limitations on
base composition are insignificant.
Production of many of the human proteins we tested was not
straightforward, and in many cases we found that only a small por-
tion of the constructs tested yielded soluble protein. To decide
which constructs to use for protein production, and to determine
the appropriate cultivation scale, all constructs were evaluated
by small-scale expression tests. Optimization of the small-scale
experiments is crucial if they are to be reliable predictors of the re-
sults of larger-scale production. We largely adopted the 1-ml
expression system described in Page et al. (2004). It is important
to monitor the growth of the small-scale cultures to ensure that
the growth rate and final densities are similar to those obtained
in the larger scale (final OD600 of 10–12 in TB medium); otherwise,
the geometry or agitation speed need to be adjusted to provide
adequate aeration. The cell pellets were solubilized with a deter-
gent/nuclease mix (Bugbuster and Benzonaze, Merck Bioscience),
centrifuged to remove insoluble material, and the recombinant
proteins are purified by Ni-affinity chromatography. The results
obtained with this combination were highly correlated with results
of subsequent large-scale experiments in which cells (from >1 L
cultures) were disrupted mechanically in absence of detergents.
In our experience, other detergent formulations tested (e.g. CelLyt-
ic from Sigma, or CHAPS) gave much less predictive results, partic-
ularly an abundance of ‘‘false positive” scores (proteins that cannot
be extracted without the specific detergent mix).
2.5. Purification
A number of factors are expected to determine the number of
steps required to purify a protein to sufficient purity and yield:
the protein’s abundance in the initial extract, the availability of
affinity purification (usually through an extraneous tag), the de-
gree of binding to contaminating proteins, the stability of the pro-
tein at different concentrations and buffer conditions, and the
difference in chromatographic properties between the target and
contaminating proteins. Expression in an efficient recombinant
system, testing multiple constructs to optimize soluble expression,
and the use of effective affinity tags (His6) resulted in soluble
expression levels of 0.5–50 mg protein/L of culture. At these
expression levels (especially at levels greater than 2 mg/L), it has
been possible to purify the majority of the proteins that were suc-
cessfully crystallized using a combination of 2–4 chromatographic
steps: nucleic acid removal (by precipitation or anion exchange
passage at high salt); Ni-affinity purification, and size-exclusion
chromatography. Additional purification could be achieved by
cleaving the purification tag with TEV protease, followed by pas-
sage on a Ni-affinity resin. As elaborated in the results, some pro-
teins required additional purification, typically ion exchange
chromatography.
2.6. Quality issues
High-throughput cloning and protein production involves qual-
ity issues in every stage. The cDNA clones used as templates for
PCR, the synthetic primers, and all of the resulting constructs
should ideally be sequence-verified. High-throughput work in-
creases the chances of cross-contamination or pipetting errors. Ex-
pressed proteins may be degraded, modified, or accompanied by
persistent contaminants. The purified proteins may represent a
mixture of aggregation states, conformers, or oxidations states.
We have addressed these issues by a combination of DNA sequenc-
ing, size-exclusion chromatography, gel electrophoresis, and elec-
trospray-ionization time-of-flight (ESI-TOF) mass spectrometry.
Table 2
Expression vectors.
Name Tag description LIC
class
Ab resistance and
compatibility
Accession
Nos.
pNIC28-Bsa4 N-terminal His6, TEV-cleavable (23 aa) MHHHHHHSSGVDLGTENLYFQ*SM 1 Kanamycin; pET EF198106
pLIC-SGC1 N-terminal His6, TEV-cleavable (23 aa) MHHHHHHSSGVDLGTENLYFQ*SM 1 Ampicillin; pET EF456737
pNIC-CTHF C-terminal His6-Flag, TEV-cleavable. AENLYFQ*SHHHHHHDYKDDDDK 2 Kanamycin; pET EF199844
pNIC-CH C-terminal His6, not cleavable. HHHHHH 3 Kanamycin; pET EF199843
pNIC-NH-TrxT N-terminal His6, Thioredoxin, TEV-cleavable 1 Kanamycin; pET GU269914
pNIC-Zb N-terminal His6, Z-basic domain (Hedhammar and Hober, 2007), TEV-cleavable. 1 Kanamycin; pET GU452710
pBEN1-SGC N-terminal SET (solubility-enhancing) and SBP
(streptavidine-binding peptide) tags, TEV-cleavable.
1 Kanamycin, pET GU725055
pFB-LIC-Bse Baculovirus cloning vector. N-terminal His6, TEV-cleavable (22 aa).
MGHHHHHHSSGVDLGTENLYFQ*SM
1 Ampicillin; transposition
in the bacterial strain
DH10Bac (InVitrogen) to
generate recombinant
baculovirus DNA
EF199842
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2.7. Data management
The SGC is a ‘paperless’ environment. Data management is cen-
tered upon an Oracle-based database with a data entry and mining
tool called BeeHive, which has been extensively modified from a
commercial version (http://www.molsoft.com/beehive.html). Bee-
Hive captures all data on targets, including cloning, purification,
crystallization and data processing. This enables immediate
assembly of all information related to a specific entity (e.g. a clone,
protein batch or crystal), as well as complex data mining on the en-
tire database (e.g. the summaries in Figs. 1, 3 and 5). A separate
electronic lab notebook (ELN), (http://www.contur.com/) is used
to record unstructured data such as experimental details, gel
images and chromatograms.
2.8. Data and clone dissemination
The full materials and methods and construct information for
all structures deposited by the SGC are available on line http://
www.sgc.ox.ac.uk/WebGallery/ (Oxford) or http://www.thes-
gc.org/structures/ (entire SGC). Expression clones for these are
available from the SGC or from partner distributors (www.add-
gene.org) as indicated in the web page or at the email address, con-
tact@sgc.ox.ac.uk. The SGC intends to make available the clones
and purification protocols for additional proteins that have not
yielded crystal structures.
3. Results and discussion
We present some statistics that summarize the degree of effort
applied to the protein targets, and some metrics of success. In par-
ticular, we attempt to evaluate the impact of several aspects of the
high-throughput methods on overall success in protein production
and structure determination.
3.1. Overall statistics
The target list included 1269 distinct human proteins (‘‘tar-
gets”), chosen from a variety of families of intracellular proteins
(when the target includes a transmembrane component, only the
intracellular domains of the target were included). The primary
goals of the SGC have been to promote biomedical research by
determining the structures of human proteins of medical rele-
vance. Part of this effort was directed at achieving extensive cover-
age of protein families, aiming to uncover the basis of specificity in
biological function and in drug action. However, the target list in-
cluded, in addition, a wide variety of structural domains: approxi-
mately 500 distinct PFAM domains. The balance between family
coverage and structural diversity is reflected in the fact that nearly
50% of the domains we examined appear only in one target,
whereas nine domains are present in >30 SGC targets, including
the catalytic domains of protein kinases, protein tyrosine phospha-
tases, and short-chain dehydrogenases/reductases, as well as PDZ
domains and bromodomains (see more detail in Supplementary
Fig. S1, Supplementary Fig. S1, panel A the target list is the balance
between proteins with different propensities to crystallize. We
have addressed this using XtalPred (Slabinski et al., 2007), looking
at all crystal structures solved by the SGC (Supplementary Fig. S1,
panel B). The analysis was carried out for the sequences of the crys-
tallized proteins (i.e. the fragment of the protein that was purified
and crystallized), as well as the corresponding full-length proteins.
One obvious feature is that a large proportion of full-length targets
are classified as very difficult, whereas the truncated proteins that
were successfully crystallized present a more balanced distribu-
tion. This observation probably reflects the fact the protein trunca-
tions were designed based on principles similar to those used in
evaluating crystallizability.
Expression and purification of each target protein was at-
tempted as multiple truncated constructs in addition to the full-
length protein; we define a successful production (‘‘productive tar-
get”) when at least one construct of a target gene leads to protein
of sufficient quantity and purity to be used in crystallization exper-
iments. 614 of the targets were productive by this measure, a suc-
cess rate of 48%. The final goal of the project is the determination of
the 3D structure of the target proteins; we have deposited 282
non-redundant structures in the PDB, representing 46% of produc-
tive targets or an overall success rate of 22%. All but three of the
structures were obtained by X-ray crystallography and the remain-
der by NMR. The full list of non-redundant structures appears in
the Supplementary material, Table S3. Note that some structures
represent separate domains from one target protein (19 additional
Fig. 1. Cloning pipeline. Distribution of the number of constructs generated per
each target (A) or each target domain combination (B). Productive targets/domains
are those for which at least one construct led to soluble, purified protein; non-
productive targets/domains could not be produced in substantial amounts from any
of the constructs generated. (C) Distribution of cloned fragments generated per
target/domain (same as panel B, but fragments cloned in different vectors are
counted only once).
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separate domains from 9 targets). Success rates calculated consid-
ering multidomain proteins can vary between 16% and 22%,
depending on the criteria used to count separate domain
combinations.
3.2. Construct design
How important is the parallel cloning and processing of multi-
ple constructs from each target? The multi-construct approach
has been described by Graslund et al. (2008); the present study ex-
tends the analysis to a larger set of target proteins. Only 31 (11%) of
the 282 structures were obtained by crystallizing the full-length
target proteins. An additional 17 structures (6%) were nearly full-
length, lacking at most 9 amino acids. Thus, more than 80% of
the structures were derived from truncated proteins. The full-
length sequence was attempted in most cases (excluding trans-
membrane and extracellular domains), but often failed either to
express or to crystallize. Thus, the generation of truncated proteins
is an essential contributor to success.
What is a reasonable number of constructs for a target? How
should construct boundaries be determined? We first look at sta-
tistics of protein expression. Fig. 1A shows the distribution of the
number of constructs generated per target; the targets are split
into productive and non-productive targets (i.e. targets that
yielded purified proteins or not). The numbers of constructs that
were made for productive targets tend to be somewhat higher than
those for non-productive targets (average constructs/target 22 and
18, respectively). The distributions trail into higher numbers, with
significant numbers of targets subcloned as >40 constructs. How-
ever, this distribution should be corrected to reflect the multido-
main arrangement of many of the target proteins. In addition to
the cloning of separate domains in non-overlapping constructs (a
minority), there are many cases where different combinations of
domains have been tested. For example, the protein kinase Fes
(PDB: 3BKB, Ref. Filippakopoulos et al. (2008)) contains three
PFAM-listed domains: an N-terminal FCH domain, an SH2 domain,
and a C-terminal kinase domain (Fig. 2A). Constructs were made
spanning all three domains, all pairwise combinations, and the
FCH and kinase domains alone. Thus, although 46 constructs were
made of the target Fes, this actually represents 4–5 separate pro-
tein entities, each addressed by 10 constructs on average. To cor-
rect the target statistics, each target and construct were analyzed
for the presence of PFAM domains, and constructs spanning differ-
ent domain combinations were scored separately (Fig. 1B). Here
the number of constructs is mostly below 40 per domain, with
an average of 13.5. In most cases, construct numbers larger than
15–20 represent parallel cloning of the same gene fragments into
different vectors (Fig. 1C). Fig. 2A also shows that construct termini
are closely spaced near well-characterized domain boundaries (e.g.
the C-terminus of the kinase domain), but more widely spaced in
regions of uncertain organization (between the FCH and SH2
domains).
All constructs were tested in small-scale expression experi-
ments (1 ml or 50 ml), and soluble expression was detected in coo-
massie-stained gels following Ni-affinity purification of the
recombinant protein. For each target/domain combination, we
have scored the fraction of constructs that expressed detectable
levels of soluble protein (a score of 1 means all constructs were po-
sitive, a score of 0.1 could mean 1 out of 10 constructs or 4 out of
40, etc.). The distribution of these scores is depicted as a histogram
in Fig. 3. We excluded from the analysis all the targets for which no
soluble expression could be seen for any of the constructs.
At first sight it is clear that, for a large proportion of productive
target/domains (39%), all constructs expressed some level of solu-
ble protein (expression levels may vary). On the other hand, there
are 15% of target/domains for which less than one in five con-
structs expressed soluble protein. This analysis seems to indicate
that, in absence of prior information, it is reasonable to start a tar-
get expression project with 10–20 constructs per domain combina-
tion. It is not discussed in this paper, but there are clear advantages
in presenting several truncated versions of a protein to crystalliza-
tion in parallel (Graslund et al., 2008). Consequently, if only 1–2
constructs generate soluble protein, it may be advisable to gener-
ate additional constructs with more closely spaced boundaries.
Which construct boundaries work best? We examine here the
construct boundaries of the 279 unique deposited crystal struc-
tures, asking the following questions. First, how do the construct
boundaries relate to the boundaries of known PFAM-annotated do-
mains? Second, how do the constructs boundaries relate to the
ends of predicted secondary structure elements? Third, how do
the construct ends relate to the actual ends of the structured re-
gions in the crystal structure? And, fourthly, are there any pre-
ferred sequence features in the unstructured ends of crystallized
constructs? To illustrate the analysis, we can look at the case of
FCH SH2 P-kinase
Fes tyrosine-protein kinaseA
PSIPRED aa 36-282
PFAM adh_short. aa 36-282
Structured region in crystal, aa 26-268
TM
B HSD11B1
Fig. 2. Schematic domain organization and construct design. Fes tyrosine-protein
kinase: the black line represents the full-length gene. The three PFAM-annotated
domains (FCH, SH2, and P-kinase) are depicted in boxes; the blue and red lines
represent the gene fragments that were all cloned and tested for expression and
crystallization. Note that the blue and red lines represent distinct constructs.
HSD11B1 (11-beta-hydroxysteroid dehydrogenase 1): a demonstration of different
definitions of structured domains.
Fig. 3. Fraction of soluble constructs per target/domain. For each productive target/
domain (as defined in Fig. 1), the fraction of constructs that tested positive for
soluble expression was scored. The proportion of domains with different fractions
of soluble constructs is displayed in histogram form.
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HSD11B1 (11-beta-hydroxysteroid dehydrogenase 1), shown sche-
matically in Fig. 2B. The length of the protein from the Genbank en-
try (gi:5031765) is 292 aa; both predictions and experiments show
the presence of a N-terminal transmembrane segment (up to aa
25) that anchors the protein to the ER. The first predicted
secondary structure element is a b-strand starting at aa 36; at
the C-terminus, a predicted a-helix ends at 282; we refer to the
region 36–282 as the predicted structured domain. This region pre-
cisely coincides with the region defined by homology to the PFAM
domain (pfam00106; adh_short).
The construct used to solve the structure extends from aa 26 to
284. In the crystal structure, (PDB ID: 2BEL) only residues from 26
to 268 are well-ordered; we refer to this region as the ‘‘ordered
domain”. The differences between the predicted structured domain
and the ordered domain result from an additional ordered segment
(10 aa) at the N-terminus including both a helical segment and 3 aa
with no secondary structure. At the C-terminus, a predicted helix
260–282 is not seen beyond aa 268. These discrepancies are quite
common, and reflect a combination of inaccuracies in predictive
methods, the presence of structured segments lacking a defined
secondary structure, and limitations of crystal structure determi-
nation (regions that are not visible may still be structured; addi-
tionally, crystal packing may influence structure).
Fig. 4 presents the distribution of lengths of unstructured ter-
mini in the constructs leading to the 279 deposited structures
(excluding the tags). Fig. 4A shows the predicted terminal unstruc-
tured sequences (these would correspond to aa 26–35 and 283–
284 in HSD11B1), while Fig. 4B shows the terminal sequences that
are disordered in the crystal structures (corresponding to aa 268–
284 in HSD11B1). Fig. 4B demonstrates the generally good coinci-
dence of the boundaries of successful constructs with the bound-
aries of the ordered regions seen in the crystals: nearly one half
of the constructs have no disordered target residues, and 80% have
less than six disordered residues on either end. It is not clear
whether the short disordered temini occur in the full-length pro-
teins or are a result of the truncation. Fig. 4A shows a wider distri-
bution of distances between the construct termini and the edges of
predicted secondary structure; this reflects the discrepancies be-
tween secondary structure predictions and observed ordered re-
gions discussed earlier. Fig. 4C shows the distribution of lengths
of construct sequences preceding or following the start and end
of annotated PFAM domains. This distribution is even wider that
that derived from secondary structure predictions, indicating that
the domain annotation should always be supplemented with sec-
ondary structure predictions when designing constructs. Finally,
we looked at the amino acid sequences of the disordered termini.
Table 3 presents the amino acid composition of all the disordered
termini compared with the overall amino acid composition of the
full construct sequences (the full sequences are presented in the
Supplementary material, Table S3). A significant trend emerges:
the disordered termini have an increased proportion of serine
and proline; a significant under-representation of hydrophobic res-
idues (particularly aromatic residues); and only modest changes in
the proportion of charged residues. This amino acid distribution is
similar to that reported in Linding et al. (2003) for coiled regions,
and is used in algorithms that predict disordered regions in
proteins.
Although this survey is far from exhaustive, the results can pro-
vide some validated guidelines on the design of constructs for pro-
tein expression and crystallization.
Fig. 4. Ends of successful constructs relative to the predicted and observed
structured regions. The constructs leading to 282 unique structures were compared
with structured regions predicted by PSIPRED (A), the observed structured region in
the crystal structure (B), and the annotated PFAM domains (C). The length of
extensions in the N-termini (white) and C-termini (full) are depicted as histograms.
Note the different scale in panel C.
Fig. 5. Presence of tags on crystallized proteins. Size distribution of proteins that
were crystallized with the tag (open) or following tag cleavage (full).
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(1) The crystal structure, if known, provides the best guide to
the design of expression constructs. The structure is rarely
known in advance, but guidance from alignments with
structures of related proteins or from NMR structures can
often be used. It is best to design multiple constructs (with
3–4 boundaries on each side), which either coincide with
the boundaries of the known structures, or include addi-
tional short sequences (typically up to 10 aa).
(2) Multiple sequence alignments and annotated conserved
domains (PFAM, CD) are a rough guide to construct design;
when several annotated domains exist (and depending on
the domain of interest), design separate series of constructs
containing different combinations of domains. After the rel-
evant domain boundaries are identified, use secondary
structure prediction methods to design construct boundaries
that do not disrupt high-likelihood structural elements.
Because of the uncertainty of these predictions, multiple
constructs should be designed spanning 1–10 aa or even
more beyond the predicted ends.
(3) Constructs termini should be preferably chosen to exclude
aromatic and other hydrophobic residues near the end,
while favouring serine and proline in short, potentially dis-
ordered stretches.
3.3. Tags, vectors and hosts
The choice of vectors and tags was dictated by the same consid-
erations that were applied in a large number of research groups; as
others have done, we have developed a series of vectors with a
number of fused tags, which can in most cases be removed by
cleavage with TEV protease (summarized in Table 2 and in Supple-
mentary Table S2). The short, cleavable tags allow us to attempt
crystallization of the same protein with or without the tag. This
proved to be beneficial, as many proteins have crystallized prefer-
entially in one form or the other. The primary choice (and the first
tag tested) is an N-terminal 23-aa peptide containing a His6 se-
quence and a TEV cleavage site. Maintaining the preference for
short tags, the second choice has been a C-terminal His6 tag (either
a cleavable, 23-aa tag that also includes a Flag epitope, or a short
non-cleavable sequence AHHHHHH). If soluble protein cannot be
recovered with short tags, longer tags comprising whole protein
domains are used: GST or Trx (E. coli thioredoxin). The thioredoxin
tag is combined with a His6 sequence to allow purification by Ni-
affinity chromatography (Vincentelli et al., 2003). It is anecdotally
known that proteins that require a large tag for soluble expression
may precipitate when the tag is removed. We have not investi-
gated this thoroughly, but significant numbers of targets have been
productively produced with GST or Trx tags and survived tag re-
moval (50 out of 70 targets attempted with GST tags, 24 out of
33 targets attempted with a Trx tag).
The impact of tag exchange has been significant: 9% of our
deposited structures were obtained with constructs bearing C-ter-
minal His6 tags. In these cases, either the N-terminally tagged con-
structs did not produce soluble protein, or failed to crystallize.
Constructs with large tags – GST and Trx – provided an additional
3% of the deposited structures. The significant chance of rescuing
expression by switching the location of the tag has driven us to
perform parallel cloning into two vectors (N-terminal and C-termi-
nal His6 tags) at the initial cloning stage, unless prior experience
with related proteins directs otherwise. The next favoured option
is a Trx fusion, which has rescued expression of several targets
and can frequently be cleaved without loss of protein solubility.
The standard hosts for bacterial expression are derivatives of
BL21(DE3). We have tested the influence of the different codon
biases in human and E. coli genes, and found that a significant
improvement in total and soluble expression levels could be
achieved by either synthesizing codon-optimized genes or provid-
ing tRNAs for rare codons in the host cells (Burgess-Brown et al.,
2008). We have used either the strain Rosetta 2 (Merck) or a
phage-resistant derivative isolated in our lab.
Specific host strains were created to co-express either accessory
proteins or heteromeric complexes. Expression of the chaperone
proteins GroEL–GroES has been useful in expression of a handful
of proteins; however, the chaperone proteins often co-purify with
the target protein and are hard to remove. We have not explored
this route extensively. Host strains expressing phosphatases
(lambda phosphatase or YopA phosphatase) have been useful for
expression of some protein kinases, which would otherwise auto-
phosphorylate.
In small-scale experiments we have observed significant varia-
tion between individual colonies from the transformation of an
expression construct into the host cells. While these differences
should be examined and the colonies with best expression selected
for further work, this may be impractical in a high-throughput set-
ting. Instead, we routinely combine several colonies from the ini-
tial transformation, achieving more reproducible results. Glycerol
Table 3
Amino acid composition of unstructured termini (tags excluded).
Amino acid 1 2 3 4 5
N-terminal disordered C-terminal disordered Total disordered termini Entire protein sequences Enrichment in termini (3/4)
Ser 11.9% (93) 10.8% (110) 11.3% (203) 6.1% (4055) 1.85
Pro 9.6% (75) 6.3% (64) 7.7% (139) 4.6% (3028) 1.70
Gln 6.1% (48) 5.4% (55) 5.7% (103) 4.3% (2854) 1.33
Glu 9.2% (72) 9.4% (95) 9.3% (167) 7.1% (4735) 1.30
Thr 4.8% (38) 7.5% (76) 6.3% (114) 5.0% (3322) 1.27
Lys 7.0% (55) 8.2% (83) 7.7% (138) 6.3% (4200) 1.21
Gly 9.9% (78) 7.9% (80) 8.8% (158) 7.3% (4835) 1.21
Ala 9.7% (76) 6.3% (64) 7.8% (140) 7.3% (4873) 1.06
Asn 3.1% (24) 4.2% (43) 3.7% (67) 3.7% (2466) 1.00
Met 2.6% (20) 2.3% (23) 2.4% (43) 2.4% (1615) 0.98
Arg 4.2% (33) 5.0% (51) 4.7% (84) 5.2% (3450) 0.90
Asp 5.1% (40) 4.5% (46) 4.8% (86) 5.3% (3543) 0.90
His 2.4% (19) 1.9% (19) 2.1% (38) 2.5% (1664) 0.84
Val 3.7% (29) 6.2% (63) 5.1% (92) 7.4% (4913) 0.69
Leu 4.8% (38) 6.5% (66) 5.8% (104) 9.5% (6342) 0.61
Cys 1.0% (8) 1.1% (11) 1.0% (19) 1.8% (1220) 0.58
Phe 1.4% (11) 2.3% (23) 1.9% (34) 3.9% (2574) 0.49
Ile 1.8% (14) 2.6% (26) 2.2% (40) 5.6% (3748) 0.39
Trp 0.38% (3) 0.49% (5) 0.44% (8) 1.2% (795) 0.37
Tyr 1.3% (10) 1.2% (12) 1.2% (22) 3.4% (2247) 0.36
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stocks made from fresh transformants can be kept for many
months at 80 C without loss of activity; ideally, several aliquots
are prepared of each stock. It is the authors’ experience that there
are isolated cases where expression can only be obtained from a
fresh transformant (e.g. yeast TATA-binding protein and Taq poly-
merase; O.G., unpublished observations); this should be checked if
expression results from glycerol stocks are inconsistent.
3.4. Expression in baculovirus-infected insect cells
A significant fraction of human targets could not be expressed
in soluble form in E. coli using the methods described above
(approximately 1/3 of the targets tested did not produce soluble
protein in small-scale or large-scale expression tests). We have
used, as an alternative method, the baculovirus expression system.
A full description of the results is beyond the scope of this paper;
the methods for high-throughput cloning and expression testing
are described elsewhere (Shrestha et al., 2008). An important
observation that has emerged is the contribution of parallel cloning
of multiple constructs of each target. Although the statistics are
still meagre, the results are similar to our experience with bacterial
expression. An example is shown in Fig. 6, where small-scale cul-
tures were used to test several constructs of two targets. Panel A
shows the substantial differences in the levels of soluble expres-
sion between different constructs: very high levels in constructs
7–11, modest levels in 3–6, and barely detectable or absent in con-
structs 1–2. Panel B shows that, similar to E. coli, protein solubility
can be the limiting factor in protein production in insect cells:
there is indication of high expression levels in the total extracts,
but the protein is lost upon centrifugation and is not seen in the
eluted fractions. Thus, effective recovery and crystallization of hu-
man proteins from the baculovirus system also requires creation
and testing multiple truncated constructs.
3.5. Purification
Protein purification may seem to be difficult to standardize, be-
cause of the wide variation in the physical and chemical properties
of different proteins. In fact, the combination of recombinant
expression and effective purification tags allowed us to use a lim-
ited set of purification protocols to achieve sufficient purity and
yield for protein crystallization (roughly scored as >95% pure,
although often of higher purity). Specific considerations when
assessing purity of proteins for crystallization are the chemical
and biophysical homogeneity of the target protein, rather than
the complete absence of other contaminating proteins. Chemical
homogeneity here means the absence of multiple chemical species
differing by oxidation, proteolysis or post-translational modifica-
tion (e.g. phosphorylation), as monitored by mass spectrometry
of the intact proteins. If heterogeneity is detected, it can be re-
solved by further chromatographic steps (e.g. ion exchange chro-
matography to resolve different phosphorylated forms), by
enzymatic treatment (e.g. phosphatase), or by modifying the
expression and purification procedure (e.g. additional protease
inhibitors and reducing agents).
Eighty-nine percent of the proteins leading to crystal structures
were purified by variants of two generic procedures. 40% of pro-
teins were purified by a two-column procedure: Ni-affinity purifi-
cation followed by size-exclusion chromatography. The second
procedure includes, in addition, tag cleavage and re-purification.
This is a very effective means of removing contaminants that bind
non-specifically to the Ni columns. Such procedures were used for
49% of the structures; the exact sequence of columns may vary (see
detailed protocols in the Supplementary material). For 9% of the
crystallized proteins, these generic procedures were not sufficient
to achieve the desired purity; in most of these cases, ion exchange
was used as an additional step.
The generic protocols work well for proteins that are at least
modestly expressed in bacteria. However, difficulties arise when
the expression levels are low, necessitating the processing of cul-
tures larger than 5 L; extraction and purification of tagged proteins
from baculovirus-infected insect cells present similar issues. The
low abundance of the proteins in the initial extracts often leads
to insufficient purity after the first steps. In addition, loading large
volumes of cell lysates on Ni-Sepharose resins leads to interference
with binding, probably due to stripping the Ni ions by some com-
ponent of the lysate (Magnusdottir et al., 2009). To alleviate some
of these problems, we have adopted the Z-basic purification tag
(Hedhammar and Hober, 2007). This 54-aa sequence, derived from
Staphylococcal protein A which was engineered to have high posi-
tive surface charge, allows tagged proteins to bind to cation-ex-
change resins at salt concentrations in which most cellular
proteins do not. A pair of LIC-vectors for use in E. coli and baculo-
virus incorporate a His10 sequence, the Z-basic tag, and a TEV
cleavage site. Preliminary evidence suggest a marked degree of
purification by combining cation exchange and Ni-affinity purifica-
tion steps, especially with proteins extracted from baculovirus
expression.
Protein stability and solubility may limit the yield or utility of
purified proteins. These are best monitored by following the activ-
ity of the protein through purification and storage. However, activ-
ity assays may not be available or practical for many of the
proteins; in these cases, alternative biophysical methods were
used. Indicators of poor stability and solubility are aberrant size-
Fig. 6. Multiconstruct testing in baculovirus. Ten constructs of one gene (A) and five constructs of a second gene (B) were cloned in baculovirus and expression was tested
following infection of 3-ml suspension cultures of SF9 cells (Shrestha et al., 2008). The cells were lysed after 48 h, the lysates were clarified by centrifugation and the
recombinant His6-tagged proteins were purified by Ni-affinity. Aliquots of the uncentrifuged total lysate (T) and the NiNTA-eluate (E) were analyzed by SDS–PAGE. The
positions of the recombinant proteins are marked with ().
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exclusion chromatography profiles, aggregation seen in dynamic
light scattering (DLS), concentration- or time-dependent precipita-
tion from solution, loss of protein during purification, and inability
to concentrate the protein using ultrafiltration. At this point it be-
comes essential to find buffer conditions or additives that increase
protein stability and solubility. In some cases it has been possible
to identify stabilizing conditions by systematic screens using fluo-
rescence or static light scattering (Vedadi et al., 2006). In other
cases, a more limited survey of conditions used precipitation or
ultrafiltration as readout. In addition to testing pH, salt composi-
tion and concentration, we have occasionally seen a positive effect
of 25% glycerol, 0.5 M trimethylamine N-oxide (TMAO) (Yancey,
2005), or a mixture of arginine and glutamate (0.2 M each); this
obviously represents a small subset of potential stabilizing addi-
tives. We have generally avoided the use of detergents to avoid po-
tential complications in crystallization of non-membrane proteins.
3.6. Quality issues
Various steps in the route from gene to purified protein can
introduce errors. Genes and cDNA clones appear in several vari-
ants, including splice variants and point differences. When possi-
ble, cDNAs were selected or synthesized according to the
Reference Sequence (RefSeq, Pruitt et al., 2007). However, variants
were tolerated when a cDNA matching the RefSeq is unavailable,
and when the variants are documented, or appear in closely related
orthologues. All cDNA entry clones were fully sequenced, either by
the supplier or in-house.
The cloning process is routinely monitored by the size of PCR-
generated DNA gel bands. Combined with the clear pedigree of
each construct, known from its position in successive 96-well
plates, this indicates the presence of inserts and the lack of gross
deletions or insertions. At a finer scale, PCR-based subcloning can
introduce sequence errors both within the primer sequences and
in the amplified region. Sequencing of a subset of constructs re-
vealed significant error rates: approximately 5% of constructs con-
tained errors in the primer sequences (often 1-base deletions), and
a further 5% contained errors within the amplified region (usually
missense). The error rate was similar for different suppliers of oli-
gonucleotide primers. It may be possible to reduce the error rates
somewhat by further purification of the primers or by using differ-
ent DNA polymerase formulations for the PCR reactions; we have
not tested these possibilities systematically. Ideally, all constructs
should be fully sequenced. In practice this has not been possible;
instead, all constructs leading to crystallized proteins, and all con-
structs which produce proteins with aberrant masses, were se-
quenced. In addition, a random subset of constructs was
sequenced to identify major changes in quality of the cloning
reagents.
The identity and quality of every protein batch is tested by mass
spectrometry. Measurement of intact mass by electrospray-ioniza-
tion time-of-flight (ESI-TOF) results in single-Dalton accuracy and
is a clear indicator of irregularities. It is crucial to attempt to ac-
count for any deviation from the predicted molecular weight. Some
changes indicate defined post-translational modification (e.g.
phosphorylation, removal of initiator methionine, acetylation,
and glycosylation), whereas others indicate protein degradation
or oxidation. Actions can be taken to reduce the heterogeneity of
the protein or to generate a desired form of the protein: for exam-
ple, dephosphorylation, autophosphorylation, site-directed muta-
genesis, and improving protease protection.
Many mass discrepancies cannot be accounted for by defined
post-translational modifications. In such cases, it is crucial to se-
quence the expression plasmid. As indicated earlier, there is a sig-
nificant incidence of primer- or PCR-derived mutations, including
missense and frameshift. Finally, in a high-throughput operation
there will be occasional mis-labeling or cross-contamination of
clones; these can sometimes be identified directly from the intact
mass. Tandem MS of trypsin-digested proteins has been used in a
more restricted basis; the main uses include identification of pro-
teins in gel bands from low-level expression and identification and
mapping of post-translational modifications.
A crucial quality issue encountered by several laboratories is
bacteriophage infection. In a high-throughput environment it is
not easy to maintain strict microbiological practices. Bacterio-
phages can be introduced either from the environment or through
clones obtained from other labs; initial sporadic infections (evident
as failed bacterial cultures) can easily spread to a lab-wide infesta-
tion which is extremely difficult to eliminate. Following a wide-
spread infection with a T1-related phage, we have introduced
two measures. First, we isolated a spontaneous phage-resistant
mutant of BL21(DE3) (reproducing the experiment of (Luria and
Delbruck, 1943), and have used this strain as the major expression
strain. In addition, all cloning is done in phage T1-resistant host
strains. Second, bacterial cultures showing any sign of bacterio-
phage infection (growth arrest or lysis, slimy or stringy appear-
ance) are decontaminated and aliquots are tested for formation
of plaques. These measures, together with increased awareness
and better microbiological practice, have helped us avoid subse-
quent infections for over 5 years. Our strains are, of course, not uni-
versally resistant, but a very rapid selection can be applied if new
infections occur.
4. Concluding remarks
Production of purified human proteins for crystallization and
biochemical studies is a challenging prospect. Data presented here
and elsewhere (e.g. Graslund et al. (2008), Banci et al. (2006)) show
that parallel processing of a modest number of constructs can im-
prove the recovery of soluble targets in both bacterial and baculo-
virus expression systems. Arguably, the selection of a well-
expressed stable version of a protein makes it easier to standardize
expression and purification protocols.
Are we approaching a ‘‘glass ceiling”, with a considerable pro-
portion of human targets inaccessible to recombinant expression?
There are clearly procedural optimizations that were not addressed
in our high-throughput work, which may lead to incremental
improvements in target expression. Many of these approaches
may be applicable in projects involving a small number of target
proteins; some can be incorporated in a high-throughput pipeline.
We have set a cut-off for productive targets such that several
milligrams of protein can be obtained from 1 to 10 L of bacterial
or insect cell culture; however, with fermentation technologies,
culture volumes of tens to hundreds of liters can be easily handled,
capturing targets expressing at lower levels. In addition, protein
expression and purification can be further optimized by utilizing
additional tags, host strains, promoters, and culture conditions
(Vincentelli et al., 2003).
Construct screening has proved an effective way of selecting
well-expressed versions of target proteins; this principle has been
extended to more extensive screening of constructs, down to full
coverage at single-residue level (Cabantous and Waldo, 2006;
Cornvik et al., 2006; Hart and Tarendeau, 2006; Reich et al.,
2006). Although these methods have led to some remarkable suc-
cesses, their impact in large-scale target recovery remains to be as-
sessed. A wide area of protein engineering that has been only
modestly exploited is mutagenesis within the protein sequence;
site-specific mutations (e.g. replacement of phosphorylation or
glycosylation sites, and deletion of disordered or hydrophobic
loops) as well as randomized mutagenesis may improve protein
recovery.
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Another approach that may be valuable is converting the host
cells to become more hospitable to expression of particular targets
by expressing a wider range of molecular chaperones, including
target-specific chaperones (e.g. HSP90 and CDC37 for protein ki-
nases; Ref. Pearl (2005)) or modifying enzymes.
A fundamentally different approach that may dominate future
progress is the expression and analysis of protein complexes (e.g.
http://www.spine2.eu). Many target proteins never occur in the
cells as isolated polypeptides, and co-expression may be the only
way to maintain the native fold of such proteins.
Finally, although the criterion of therapeutic value has pre-
scribed a focus on human proteins, there may be cases when ortho-
logues from other organisms may be the only choice; small
differences in sequence may significantly affect success in expres-
sion and crystallization (Savchenko et al., 2003).
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